已收盤 11-20 16:00:00 美东时间
0.000
0.00%
今日重点评级关注:摩根士丹利:维持Riot Platforms"超配"评级,目标价从35.5美元升至41美元;Canaccord Genuity:维持塞德斯医疗"买入"评级,目标价从60美元升至68美元
11-10 18:30
HC Wainwright & Co. analyst Yi Chen reiterates Envoy Medical (NASDAQ:COCH) with a Buy and announces $18 price target.
11-09 19:32
Envoy Medical (NASDAQ:COCH) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.c...
11-05 21:44
Envoy Medical (NASDAQ:COCH) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.67) by 25.37 percent. This is a 42.86 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $66.000 thousand...
11-05 20:46
Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it will implement a 1-for-10 reverse stock split of its outstanding shares of Class A common stock ("Common Stock"), ...
10-22 20:36
今日重点评级关注:Jones Trading:维持Opus Genetics"买入"评级,目标价从10美元升至17美元;Citizens:维持Rezolute"跑赢大市"评级,目标价从11美元升至15美元
10-07 17:30
Lake Street analyst Frank Takkinen initiates coverage on Envoy Medical (NASDAQ:COCH) with a Buy rating and announces Price Target of $2.5.
10-07 03:56
Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the grant of two additional international patents, expanding its global intellectual property portfolio to 97 patents, consisting of 40 U.S. an...
09-22 20:35
今日重点评级关注:摩根士丹利:维持Ultragenyx Pharmaceutical"超配"评级,目标价从67美元升至74美元;Truist Securities:维持Solid Biosciences"买入"评级,目标价从16美元升至20美元
08-24 16:40
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird raised the price target for Parsons Corp (NYSE:PSN) from $48 to $57. Baird analyst Andrew Wittmann upgra...
08-21 20:24